COSCIENS Biopharma Inc. (CSCIF) COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Sector: Perfumes, Cosmetics & Other Toilet Preparations
Industry: Medical - Pharmaceuticals
COSCIENS Biopharma Inc. OTC:CSCIF Healthcare · Medical - Pharmaceuticals
All Press Release SEC Filings News
SEC Filing ● Major ⚠ 2
CSCIF: 15-12G · other
COSCIENS Biopharma Inc. filed a Form 15 to terminate the registration of its Common Shares under Section 12(g) of the Securities Exchange Act of 1934. The company also suspended its duty to file reports under Sections 13 and 15(d) of the Act, citing compliance with specific rules regarding the number of record holders.
The filing indicates that the approximate number of holders of record is 153. By relying on Rules 12g-4(a)(1) and 12h-3(b)(1)(i), the company meets the criteria to cease public reporting.
This action effectively takes the company private, ending its obligation to file periodic reports like 10-Ks and 10-Qs. The move significantly reduces transparency and liquidity for remaining investors.
SEC 15-12G • 3mo ago SEC Filing ● Major ⚠ 3
CSCIF: 6-K · reverse split
COSCIENS Biopharma Inc. completed a share capital amendment effective July 3, 2026, combining a 1-for-150 consolidation with a subsequent 50-for-1 split. The net result reduces the number of common shares outstanding by a factor of three, effectively constituting a 1-for-3 reverse stock split. Shareholders holding fewer than 150 pre-consolidation shares received a cash payment of US$1.60 per share in lieu of new shares.
The company intends to file a Form 15 with the SEC to voluntarily suspend its reporting obligations under the Securities Exchange Act of 1934. This move relieves the company of associated costs and administrative burdens but raises uncertainty regarding the continued eligibility of its shares for trading on the OTCQB Venture Market. Shares are expected to continue trading on the Toronto Stock Exchange under the symbol CSCI within two business days.
SEC 6-K • 3mo ago AI analysis › SEC Filing ● Major ⚠ 3
CSCIF: 6-K · reverse split
COSCIENS Biopharma Inc. announced the approval of a Share Capital Amendment at its annual general meeting, which includes a consolidation of common shares on a 1-for-150 basis followed immediately by a 50-for-1 split. This transaction results in a net reduction of shareholders' pre-consolidation holdings by a factor of three and is expected to become effective on July 3, 2026.
Shareholders holding fewer than 150 common shares as of the effective date will receive cash consideration of $1.60 per share, while those with 150 or more shares will receive replacement shares reflecting the new structure. The Company plans to file a Form 15 with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934.
The extreme consolidation mechanics and the planned suspension of SEC reporting mark a significant shift in the company's public market structure and transparency.
SEC 6-K • 4mo ago AI analysis › SEC Filing ⚠ 1
CSCIF: 6-K · proxy statement
Shareholders approved all proposals at the annual general meeting, including the re-election of the board of directors and the re-appointment of Deloitte LLP as auditors. Peter H. Puccetti, who served as Interim CEO since November, was appointed permanent President and Chief Executive Officer effective immediately.
The meeting also authorized a share capital amendment involving a consolidation of common shares on a 1-for-150 basis followed by a 50-for-1 split. This results in a net 3-for-1 consolidation of issued and outstanding shares.
Voting results showed strong support for management, with the share capital amendment receiving approximately 85% of votes cast.
SEC 6-K • 4mo ago AI analysis › SEC Filing
CSCIF: 6-K · proxy statement
COSCIENS Biopharma Inc. filed a Form 6-K to announce that its board of directors has passed a resolution to convene a Special Meeting of Shareholders. The meeting is scheduled to take place on June 17, 2026, at 9:30 am Eastern time.
The filing includes the Management Proxy Circular and a form of proxy, which were sent to shareholders on or before May 21, 2026. This is a standard procedural disclosure required for foreign private issuers notifying shareholders of upcoming meetings.
SEC 6-K • 5mo ago AI analysis › SEC Filing ⚠ 5
CSCIF: 6-K · periodic report
COSCIENS Biopharma Inc. reported its first-quarter 2026 financial results, revealing a consolidated net income of $10.8 million, a significant turnaround from a net loss of $3.7 million in the prior-year period. This swing is primarily driven by a one-time gain of $10.9 million from the deconsolidation of its German subsidiaries, which were classified as discontinued operations following insolvency proceedings in March 2026.
Revenue from continuing operations increased 36% to $1.9 million, bolstered by higher sales volumes, while gross margin improved to 42%. Despite the top-line growth, the company recorded a net loss from continuing operations of $0.2 million, reflecting continued operational challenges. The company's cash position decreased to $5.0 million from $7.3 million at year-end 2025.
Management noted substantial doubt about the company's ability to continue as a going concern due to sustained revenue declines and historical operating losses. However, they stated that cash on hand and projected future cash flows are expected to be sufficient to cover liabilities for at least the next twelve months. The company also announced plans to suspend SEC reporting obligations pending shareholder approval of a proposed share reorganization.
SEC 6-K • 5mo ago AI analysis › Press Release
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
globenewswire.com • 6mo ago Press Release
COSCIENS Comments on Unusual Market Activity
globenewswire.com • 6mo ago Press Release ● Major
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com • 7mo ago Press Release
COSCIENS Provides Strategic Update
globenewswire.com • 7mo ago 
